2008 ASCO Genitourinary Cancers Symposium: Updates in the Management of Prostate and Kidney Cancers - CME
C. Dean Buckner, MD

ASCO 2007: Update on the Management of Genitourinary Malignancies
Nancy A. Dawson, MD – Lombardi Comprehensive Cancer Center

Urinary Prostate Cancer Test, PCA3, Predictive of Biopsy Outcomes (3/9/2010)
Researchers involved in the international Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial have reported that the urinary PCA3 test can predict biopsy outcome in men taking dutasteride. The details of two studies were presented at the 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium held in San Francisco, March 5-7.

Gene Signature Test May Help Predict Recurrences of Prostate Cancer After Prostatectomy (3/8/2010)
Researchers from the University of Texas at San Antonio, the University of Utah, and Myriad Genetics, Inc. have reported that a gene signature test performed on prostate cancer tissue can help predict the probability of recurrent disease in men with localized prostate cancer treated with radical prostatectomy. The details of this study were presented at the 2010 meeting of the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium March 5-7 in San Francisco.

Cabazitaxel Effective for Hormone Refractory Prostate Cancer After Failure of Taxotere® (3/5/2010)
Researchers involved in the multicenter international Phase III trial (TROPIC) have reported that cabazitaxel (XRP-6258) was superior to Novantrone® (mitoxantrone) for the treatment of patients with hormone refractory prostate cancer (HRPC) who had failed treatment with Taxotere® (docetaxel). The details of this study were presented at the 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium March 5-7 in San Francisco.

Long-term Results Confirm Benefit of High-dose Conformal Radiation for Early-stage Prostate Cancer (3/4/2010)
Researchers affiliated with the Proton Radiation Oncology Group/American College of Radiology 95-09 study have concluded that high-dose conformal radiation therapy results in better long-term cancer control than conventional-dose radiation therapy for treatment of localized prostate cancer. The details of this follow-up study were published in the March, 2010 issue of the Journal of Clinical Oncology.

Abiraterone, an Inhibitor of Cytochrome P17, Confirmed Effective in Hormone Refractory Prostate Cancer (3/3/2010)
Three studies published early online in the Journal of Clinical Oncology on February 16, 2010 have confirmed that abiraterone acetate, an inhibitor of cytochrome P17, is active in men with hormone refractory prostate cancer (HRPC). These studies also suggest that patients who cease to respond to current androgen depravation therapy (ADT) will respond to an alternative form of androgen deprivation.